<DOC>
	<DOC>NCT00810485</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors</brief_summary>
	<brief_title>ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>diagnosis of typical GERD partial responder to a stable standard clinical symptoms control dose of PPI therapy body mass index â‰¤ 32 kg/m2 exclusively atypical symptoms of GERD symptoms that have been shown not to be associated with GERD erosive oesophagitis treated with a dose of PPI greater than the dose indicated for clinical symptom control of GERD hiatus hernia &gt; 3 cm current diagnosis of coexisting psychiatric disease known clinical significant allergy or known hypersensitivity to drugs is pregnant or breastfeeding has received sodium valproate or topiramate within 30 days of Screening has a history of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Gastroesophageal reflux</keyword>
	<keyword>Proton pump inhibitor</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Regurgitation</keyword>
</DOC>